Teladoc Health (NYSE:TDOC) Stock Rating Upgraded by Bank of America

Teladoc Health (NYSE:TDOC) was upgraded by Bank of America from a “neutral” rating to a “buy” rating in a report released on Thursday, Marketbeat Ratings reports. The brokerage currently has a $7.00 price objective on the health services provider’s stock. Bank of America‘s price target indicates a potential upside of 32.95% from the stock’s previous close.

Several other research firms have also recently commented on TDOC. Citigroup lowered their target price on Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Friday, January 9th. Barclays assumed coverage on Teladoc Health in a report on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price target on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a research note on Monday, December 29th. Piper Sandler reiterated an “overweight” rating and issued a $9.00 target price (down from $12.00) on shares of Teladoc Health in a research report on Thursday. Finally, Evercore dropped their price target on shares of Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research report on Thursday, October 30th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.50.

Teladoc Health Stock Up 13.2%

NYSE TDOC traded up $0.62 on Thursday, hitting $5.27. 13,602,156 shares of the stock traded hands, compared to its average volume of 6,744,879. The company has a current ratio of 2.70, a quick ratio of 2.60 and a debt-to-equity ratio of 0.71. The stock has a 50-day moving average of $6.06 and a 200 day moving average of $7.22. Teladoc Health has a twelve month low of $4.40 and a twelve month high of $10.02. The company has a market capitalization of $934.38 million, a P/E ratio of -4.11 and a beta of 2.12.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.The business had revenue of $642.27 million for the quarter, compared to analyst estimates of $635.33 million. During the same period in the prior year, the company posted ($0.28) EPS. The business’s revenue was up .3% compared to the same quarter last year. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. As a group, analysts expect that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In other news, insider Adam C. Vandervoort sold 5,720 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $42,842.80. Following the completion of the sale, the insider owned 80,732 shares in the company, valued at approximately $604,682.68. This represents a 6.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Carlos Nueno sold 3,897 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total value of $29,188.53. Following the sale, the insider directly owned 27,175 shares of the company’s stock, valued at approximately $203,540.75. This represents a 12.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 33,288 shares of company stock worth $251,684. 0.58% of the stock is owned by corporate insiders.

Institutional Trading of Teladoc Health

Large investors have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas lifted its stake in Teladoc Health by 5.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 26,592 shares of the health services provider’s stock worth $232,000 after acquiring an additional 1,431 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of Teladoc Health by 0.5% in the 3rd quarter. Federated Hermes Inc. now owns 307,700 shares of the health services provider’s stock valued at $2,379,000 after purchasing an additional 1,450 shares during the period. Creative Planning lifted its position in shares of Teladoc Health by 7.7% in the third quarter. Creative Planning now owns 20,567 shares of the health services provider’s stock worth $159,000 after purchasing an additional 1,462 shares in the last quarter. Krane Funds Advisors LLC boosted its holdings in shares of Teladoc Health by 13.4% during the third quarter. Krane Funds Advisors LLC now owns 12,431 shares of the health services provider’s stock worth $106,000 after purchasing an additional 1,469 shares during the period. Finally, State of Wyoming grew its position in Teladoc Health by 2.1% during the third quarter. State of Wyoming now owns 79,075 shares of the health services provider’s stock valued at $611,000 after purchasing an additional 1,628 shares in the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 results beat expectations — Teladoc reported revenue of $642.3M (above $635.3M consensus) and EPS of ($0.14), topping estimates. The beat reduces near‑term earnings uncertainty and provides proof of stabilization after prior losses. Q4 sales surprise
• Positive Sentiment: Conference call highlighted growth in Integrated Care and strategic repositioning of BetterHelp — management emphasized areas of improving unit economics and product focus that could drive margin recovery over time. Investors often reward visible operational progress even when near‑term guidance is cautious. Earnings call highlights
• Neutral Sentiment: Deeper metric readouts available — analysts and outlets (e.g., Zacks) are parsing subscriber, utilization and margin metrics to assess sustainability of the beat; these details will influence revisions to models but don’t yet change the headline picture. Zacks analysis
• Negative Sentiment: Forward guidance disappointed — Q1 2026 EPS guidance of -0.450 to -0.350 and FY 2026 EPS of -1.100 to -0.700 both sit below consensus; Q1 revenue guidance ($598M–$620M) is also below Street estimates. This increases near‑term downside risk and keeps profitability recovery uncertain. Guidance details
• Negative Sentiment: Analysts cut price targets — Wells Fargo and Stifel reduced targets from $8 to $6 and kept neutral/hold stances, signaling tempered expectations for upside and contributing to mixed sell‑side sentiment. Benzinga

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.